India Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

India Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary

The India Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $332 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.1% from 2022 to 2030 and will reach $717 Mn in 2030. Chronic Obstructive Pulmonary Disease (COPD) is a "common preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation due to abnormalities in the airway and (or) alveolar abnormalities usually caused by significant exposure to noxious particles or gases”. The World Health Organization (WHO) lists COPD as one of the major causes of death worldwide. The reduction of the global burden of respiratory diseases is a shared commitment of the WHO Global Partnership against Chronic Respiratory Disorders. Due to expensive medical expenses and a reduced quality of life related to one's health, COPD also places a heavy burden on society. It is the most common chronic respiratory disease to cause impairment and was the second-leading cause of Disability Adjusted Life Years (DALY) in 2016.

The prevalence of COPD (chronic obstructive pulmonary disease) is highest in India. The number climbed from 28.1 million in the 1990s to 55.3 million in 2016, according to the Lancet Respiratory Medicine article. According to the Indian Study on Epidemiology of Asthma, Respiratory Symptoms, and Chronic Bronchitis in Adults, India significantly contributes to the morbidity and mortality of COPD in the world, with 3% of India's disability-adjusted life years (DALYs) being recorded due to chronic respiratory diseases (CRDs) (INSEARCH). The primary cause of CRDs is COPD, which must be noted and understood. Several studies estimate that the yearly economic cost of COPD to be more than 48,000 crores, which is significantly greater than the Ministry of Health and Family Welfare's annual budget (MOHFW) of 2010-2011.

Market Dynamics

Market Growth Drivers

According to a study published in the Journal of Family Medicine and Primary Care India in 2020, the prevalence of COPD in is around 4.2%. The study also projected that the prevalence of COPD in India will continue to increase in the coming years, primarily due to rising smoking rates, air pollution, and aging population. This increasing prevalence of COPD is driving the demand for COPD therapeutics in India. The Indian government and various organizations have been taking steps to raise awareness about COPD and its risk factors. For instance, the Indian Chest Society launched the "Breathefree" initiative in 2012 to increase awareness about COPD and provide access to affordable COPD therapeutics. This rising awareness about COPD is expected to drive the demand for COPD therapeutics in India. Government initiatives: The Indian government has taken several initiatives to promote the use of COPD therapeutics in the country. For instance, in 2020, the Ministry of Health and Family Welfare launched the "National Chronic Obstructive Pulmonary Disease (COPD) Program" to improve the diagnosis and treatment of COPD in the country. This initiative is expected to drive the demand for COPD therapeutics in India. Growing healthcare infrastructure: India has been investing heavily in improving its healthcare infrastructure in recent years. According to a report, India's healthcare market is expected to grow at a CAGR of 22% between 2020 and 2025. This growing healthcare infrastructure is expected to increase access to COPD therapeutics in India and drive the growth of the India COPD therapeutics market. Several players in the India COPD therapeutics market are focusing on developing new and innovative COPD therapeutics. For instance, in 2020, Glenmark Pharmaceuticals launched a new inhaler for the treatment of COPD in India. This product innovation is expected to drive the demand for COPD therapeutics in India.

Market Restraints

Despite efforts by the government and various organizations, many people in India are still not aware of COPD and its risk factors. This lack of awareness can lead to underdiagnosis and undertreatment of COPD, which can hinder the growth of the India COPD therapeutics market. COPD therapeutics can be expensive, especially for patients who require long-term treatment. Many people in India may not be able to afford the cost of COPD therapeutics, which can limit the demand for these drugs. Despite the growing healthcare infrastructure in India, many people still have limited access to healthcare, especially in rural areas. This limited access to healthcare can make it difficult for people with COPD to receive timely and adequate treatment, which can hinder the growth of the India COPD therapeutics market. In addition to COPD therapeutics, there are several alternative therapies available for the treatment of COPD, such as traditional medicines and home remedies. These alternative therapies can compete with COPD therapeutics and limit the growth of the India COPD therapeutics market. The Indian regulatory environment for pharmaceuticals is known to be strict, and companies must adhere to strict regulations to obtain approval for their products. This can increase the cost and time required for product development and hinder the growth of the India COPD therapeutics market.

Competitive Landscape

Key Players

• Cipla
• Glenmark Pharmaceuticals
• Lupin Limited
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals
• AstraZeneca
• Boehringer Ingelheim Pharmaceuticals
• Novartis
• Pfizer
• Teva India Limited

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Family Welfare is responsible for formulating and implementing healthcare policies in India. The ministry oversees several departments, including the Department of Health and the Department of Family Welfare.

Central Drugs Standard Control Organization (CDSCO) responsible for regulating the import, manufacture, distribution, and sale of pharmaceuticals in India. The organization is responsible for granting approvals for drugs, medical devices, and clinical trials. National Pharmaceutical Pricing Authority (NPPA) is responsible for fixing and regulating the prices of drugs in India. The organization ensures that the prices of essential drugs are affordable and accessible to all. Drugs Controller General of India (DCGI) is responsible for regulating the safety, efficacy, and quality of drugs in India. The organization oversees the approval of new drugs, clinical trials, and post-marketing surveillance.

Indian Pharmacopoeia Commission (IPC) is responsible for setting standards for drugs in India. The commission develops and publishes the Indian Pharmacopoeia, which is a book of standards for drugs in India. The government has taken several initiatives to improve the healthcare system in India, including the launch of the Ayushman Bharat scheme, which aims to provide free healthcare to millions of people in India.

Reimbursement Scenario

In general, COPD treatment in India is covered by both public and private insurance schemes, but the reimbursement rates vary widely. Public insurance schemes, such as the Rashtriya Swasthya Bima Yojana (RSBY) and Ayushman Bharat, provide coverage for COPD treatment, but the reimbursement rates may not cover the full cost of treatment. Private insurance schemes may provide more comprehensive coverage, but the premiums can be expensive and not all individuals have access to private insurance. In addition, the reimbursement scenario for COPD treatment can vary depending on the type of healthcare provider. Treatment in government hospitals and clinics may be more affordable and accessible for low-income individuals, but these facilities may have limited resources and long wait times. Private healthcare providers may offer more personalized care and better facilities, but the costs can be higher.